Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PER Pulse™ Recaps
for Rapid Summaries and Commentaries™: Update from Chicago: Advances in Lung Cancer focus on next-generation ALK tyrosine kinases, new classes of oncogenic drivers, including BRAF V600E mutations and MET exon 14 alterations, and investigation of combination immunotherapy in the first-line setting in patients with non-small-cell lung cancer.
This activity is supported by educational grants from Novartis Pharmaceuticals Corporation.
This activity is designed to update physicians on recent data sets presented at the Chicago meeting, so that practitioners, who manage patients with lung cancer, can assess and consider how these findings apply to their clinical practices. Some key trial information was presented at the meeting on targeted agents in patients with actionable molecular markers, emerging biomarkers, how recent findings may impact decision making when sequencing therapies, and early-phase clinical trial results concerning the use of front-line immunotherapy in non-small cell lung cancer.
Instructions For This Activity & Receiving Credit
This educational activity is directed toward medical oncologists and fellows who treat patients with lung cancers. Surgical oncologists, radiation oncologists, pulmonologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung may also participate.
David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Disclosure: Research Grants: AstraZeneca/Medi, Bristol-Myers Squibb, Clovis, Genentech, Johnson & Johnson, Lilly, Merck, Novartis; Consultant: AstraZeneca, Boehringer-Ingelheim, Celgene, Clovis, Genentech, Guardant Health, Lilly, Merck, Novartis, Pfizer, Synta.
The following individuals have no relevant financial relationships with commercial interests:
The staff of PER®, LLC.
It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell Tumors
Apr 28, 2018
April 28, 2018
New York, NY